23andMe Holding (ME) has released an update to notify the public and investors about a regulation fd disclosure.
23andMe Holding Co. announced that the FDA has approved their investigational new drug application for a novel cancer treatment, 23ME-01473, which activates Natural Killer cells. The drug will be tested in a Phase 1 clinical study on patients with advanced solid tumors starting in the first half of 2024.
For further insights into ME stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
